Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: Serum inflammatory biomarkers, clinical efficacy, and microbiological eradication

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 55-64

  Blasi, Francesco ^a   Tarsia, Paolo ^a   Mantero, Marco ^a   Morlacchi, Letizia C ^a   Piffer, Federico ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute exacerbations; Cefditoren pivoxil; Chronic bronchitis; Levofloxacin; Serum inflammatory biomarkers

Indexed keywords

BIOLOGICAL MARKER; CEFDITOREN; INTERLEUKIN 6; KREBS VON DEN LUNDGEN 6; LEVOFLOXACIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD LEVEL; BLOOD OXYGEN TENSION; CHRONIC BRONCHITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG INJURY; MALE; NAUSEA; OUTPATIENT CARE; PILOT STUDY; PNEUMONIA; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL;

EID: 84875422453     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S41131     Document Type: Article

References (65)

1. Kim N, Leeper KV Jr. Epidemiology of chronic bronchitis and acute infective exacerbations of chronic bronchitis. Semin Respir Crit Care Med. 2000;21(2):73-78.
2. Bousquet J, Kiley J, Bateman ED, et al. Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J. 2010;36(5):995-1001.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498-1504.
4. Anthonisen NR, Manfreda J, Warren PC, Hershfield EC, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204.
5. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157(5 Pt 1):1418-1422.
6. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-931.
7. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852.
8. Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001;164(3):358-364.
9. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091-1097.
10. Reynolds HY. Chronic obstructive pulmonary disease, chronic bronchitis, and acute exacerbations. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Disease, 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005.
11. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org. Accessed November 10, 2012.
12. 1 - time to divide and conquer? N Engl J Med. 2008;359(15):1616-1618.
13. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355-2365.
14. Hayes D Jr, Meyer KC. Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management. Drugs Aging. 2007;24(7):555-572.
15. Mensa J, Trilla A. Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones. Clin Microbiol Infect. 2006;12 Suppl 3:42-54.
16. Sethi S. Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2005;26(2):192-203.
17. Chiba S, Ohta H, Abe K, et al. The diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of fibrosis in combined pulmonary fibrosis and emphysema. Pulm Med. 2012;2012:492960.
18. Arai S, Kurasawa K, Maezawa R, Owada T, Okada H, Fukuda T. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/ dermatomyositis. Mod Rheumatol. September 17, 2012. [Epub ahead of print.]
19. Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/ MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012;50(1):3-13.
20. Blasi F, Bulfoni A, Concia C, et al. Attualita' nella gestione delle infezioni delle basse vie respiratorie in medicina interna. [Management of lower respiratory tract infections in internal medicine]. Italian Journal of Medicine. 2012;4(1):42-53. Italian.
21. Petitpretz P, Choné C, Trémolières F; Investigator Study Group. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents. 2007;30(1):52-59.
22. Alvarez-Sala JL, Kardos P, Martínez-Beltrán J, Coronel P, Aguilar L. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother. 2006;50(5):1762-1767.
23. Wilson R, Langan C, Ball P, Bateman K, Pypstra R; Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med 2003;97(3):242-249.
24. Weiss LR. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin Ther. 2002;24(9):1414-1425.
25. Anzueto A, Bishai WR, Pottumarthy S. Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis. Diagn Microbiol Infect Dis. 2007;57(Suppl 3):31S-38S.
26. Dubois J, St-Pierre C. In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. Diagn Microbiol Infect Dis. 2000;37(3):187-193.
27. Gracia M, Díaz C, Coronel P, et al. Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program. Diagn Microbiol Infect Dis. 2009;64(1):52-56.
28. Tempera G, Furneri PM, Carlone NA, et al. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren. J Chemother. 2010;22(3):153-159.
29. Tempera G, Furneri PM, Ferranti C, et al. In vitro activity of cefditoren versus other antibiotics against S. pneumoniae clinical strains isolated in Italy. Int J Immunopathol Pharmacol. 2010;23(3): 833-840.
30. Gracia M, Díaz C, Coronel P, et al. Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central, East and Baltic European countries in 2005-2006: results of the Cefditoren Surveillance Study. J Antimicrob Chemother. 2008;61(5):1180-1181.
31. García-de-Lomas J, Lerma M, Cebrián L, et al. Influence of Haemophilus influenzae beta-lactamase production and/or ftsI gene mutations on in vitro activity of and susceptibility rates to aminopenicillins and second- and third-generation cephalosporins. Int J Antimicrob Agents. 2007;30(2):190-192.
32. Barberán J, Aguilar L, Giménez MJ. Update on the clinical utility and optimal use of cefditoren. Int J Gen Med. 2012;5:455-464.
33. Soriano F, Giménez MJ, Aguilar L. Cefditoren in upper and lower community-acquired respiratory tract infections. Drug Des Devel Ther. 2011;5:85-94.
34. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. Efficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials. Spanish. Rev Esp Quimioter. 2008;21(1):14-21. Spanish.
35. Granizo JJ, Aguilar L, Gimenez MJ, Coronel P, Gimeno M, Prieto J. Safety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infections. Rev Esp Quimioter. 2009;22(2):57-61. Spanish.
36. Shah PM, Maesen FP, Dolmann A, Vetter N, Fiss E, Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. J Antimicrob Chemother 1999;43(4):529-539.
37. Yanbaeva DG, Dentener MA, Spruit MA, et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a casecontrol study. BMC Med Genet. 2009;10:23.
38. Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012;8(9):1281-1290.
39. Grubek-Jaworska H, Paplińska M, Hermanowicz-Salamon J, et al. IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests. Respiration. 2012;84(2):101-107.
40. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065-1072.
41. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.
42. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000;84(2):210-215.
43. Nathani N, Perkins GD, Tunnicliffe W, Murphy N, Manji M, Thickett DR. Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome. Crit Care. 2008;12(1):R12.
44. Sato H, Callister ME, Mumby S, et al. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J. 2004;23(1):142-145.
45. Ishizaka A, Matsuda T, Albertine KH, et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2004;286(6):L1088-L1094.
46. Doishita S, Inokuma S, Asashima H, et al. Serum KL-6 level as an indicator of active or inactive interstitial pneumonitis associated with connective tissue diseases. Intern Med. 2011;50(23):2889-2892.
47. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med. 2006;260(5):429-434.
48. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006; 11(2):164-168.
49. Ishikawa N, Mazur W, Toljamo T, et al. Ageing and long-term smoking affects KL-6 levels in the lung, induced sputum and plasma. BMC Pulm Med. 2011;11:22.
50. Ishikawa N, Hattori N, Tanaka S, et al. Levels of surfactant proteins A and D and KL-6 are elevated in the induced sputum of chronic obstructive pulmonary disease patients: a sequential sputum analysis. Respiration. 2011;82(1):10-18.
51. Henry DC, Poling TL, Bettis RB. A double-blind, randomized study of cefditoren vs cefuroxime for AECB. J Respir Dis. 2001;22 Suppl 8: 69-74.
52. Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Am J Med. 2001; 111 Suppl 9A:4S-12S.
53. Slama TG, Amin A, Brunton SA, et al. A clinician's guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria. Am J Med. 2005; 118 Suppl 7A:1S-6S.
54. Martinez FJ, Anzueto A. Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Am J Med. 2005; 118 Suppl 7A:39S-44S.
55. Scaglione F, Bertazzoni Minelli E, De Sarro A, et al. The Charta of Milan: basic criteria for the appropriate and accurate use of antibiotics: recommendations of the Italian Society of Chemotherapy. J Chemother. 2009;21(5):475-481.
56. Levy-Hara G, Amábile-Cuevas CF, Gould I, et al. "Ten Commandments" for the appropriate use of antibiotics by the practicing physician in an outpatient setting. Front Microbiol. 2011;2:230.
57. Canut A, Martin-Herrero JE, Labora A, Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J Antimicrob Chemother. 2007;60(3):605-612.
58. Blasi F, Concia E, Mazzei T, et al. Role of the oral beta-lactams in the treatment of exacerbations of chronic bronchitis: critical analysis and therapeutic recommendations. J Chemother. 2010;22 Suppl 1:3-30.
59. Pugi A, Longo L, Bartoloni A, et al. Cardiovascular and metabolic safety profiles of the fluoroquinolones. Expert Opin Drug Saf. 2012;11(1):53-69.
60. Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis. 2012;55(11):1457-1465.
61. Paterson JM, Mamdani MM, Manno M, Juurlink DN; for the Canadian Drug Safety and Effectiveness Research Network. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ. 2012;184(14):1565-1570.
62. Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012;307(13): 1414-1419.
63. Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27(3):193-209.
64. Lode H. Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections. Am J Med. 2010; 123(Suppl 4):S26-S38.
65. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections - summary. Clin Microbiol Infect. 2011;17 Suppl 6:1-24.